News Releases

Apr 29, 2020
SHANGHAI, China and ROCKVILLE, MD., April 29, 2020 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet
Apr 24, 2020
SHANGHAI, China and ROCKVILLE, MD., April 24, 2020 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet
Apr 06, 2020
SHANGHAI, China, and ROCKVILLE, MD., April 06, 2020 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet
Mar 27, 2020
Fernando J. Sallés, Ph.D., CLP ® , Appointed to Lead I-Mab’s U.S. and EU Business Development SHANGHAI, China and ROCKVILLE, MD., March 27, 2020 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and
Displaying 11 - 20 of 26